Rainier Therapeutics rainerrx.com


Public list: BIO 2016 (619) Pharma Startups (4734) Cancer Therapeutics (1145)

Rainier Therapeutics is a privately-held clinical stage drug development company developing a first-in-class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody in areas of high unmet medical need. The company's lead development candidate, B-701, is a human antibody for the treatment of patients with metastatic bladder cancer, or metastatic urothelial carcinoma (mUC), who have relapsed or are refractory to platinum therapy.

Rainier Therapeutics is a privately-held clinical stage drug development company developing a first-in-class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody in areas of high unmet medical need. The company's lead development cand...Show all

Company (Alive / Active)

Phone: 925-413-6140

Fax:

1040 Davis Street
#202
San Leandro, 94577
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Rainier Therapeutics $76M Feb 12, 2019

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Rainier Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 10 investors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Methods, compositions, and kits for treatment of cancer Feb 19, 2016 Application